Auris aims to bounce back with King's collaboration

23 February 2017

Auris Medical Holding (Nasdaq: EARS), a clinical-stage company developing therapeutics in otolaryngology, has announced the extension of its collaboration with King's College London.

The collaboration with the UK university is focused on the discovery of small molecule compounds for a second-generation tinnitus treatment and will result in the selection of a lead compound for the company's AM-102 program.

Auris' AM-101 program in acute inner ear tinnitus suffered a major setback in August 2016 when its agent Keyzilen did not meet the co-primary efficacy endpoints in a Phase III trial of statistically-significant changes in tinnitus loudness and tinnitus burden, compared to placebo, wiping nearly 60% off the company's share price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK